Studies have shown that disruption of the blood–brain barrier contributes to APOE4-associated cognitive decline, which may be a therapeutic target for Alzheimer’s disease (Montagne et al., 2020). Here, APOE is linked to early-onset autosomal dominant Alzheimer disease.